MYC and cancer: This is particularly relevant given that the SUMO cycle is dysregulated in multiple myeloma, has been associated with an adverse outcome in cancer patients [80], and inhibition of a SUMOylation-dependent transcriptional program induces death of MYC-over-expressing cancer cells [81].